CLINICAL RESEARCH: HEART RHYTHM DISORDER
High Sensitivity C-Reactive Protein
A Novel Predictor for Recurrence of Atrial Fibrillation After Successful Cardioversion
Joseph F. Malouf, MD,
Ravi Kanagala, MD,
Faisal O. Al Atawi, MD,
A. Gabriela Rosales, MS,
Diane E. Davison, MA, RN,
Narayana S. Murali, MBBS,
Teresa S.M. Tsang, MD,
Krishnaswamy Chandrasekaran, MD,
Naser M. Ammash, MD,
Paul A. Friedman, MD and
Virend K. Somers, MD, PhD*
Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota
Manuscript received March 24, 2005;
revised manuscript received May 28, 2005,
accepted June 6, 2005.
* Reprint requests and correspondence: Dr. Virend K. Somers, Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905. (Email: somers.virend{at}mayo.edu).
OBJECTIVES: We sought to test the hypothesis that C-reactive protein (CRP) can predict the recurrence of atrial fibrillation (AF) after successful electrical cardioversion (CV).
BACKGROUND: In patients with AF, CRP levels are predictive of immediate failure of CV.
METHODS: We prospectively measured high-sensitivity CRP in 67 patients with AF or atrial flutter who underwent successful electrical CV.
RESULTS: At one-month follow-up, 22 patients (33%) had recurrence of their arrhythmia. Arrhythmia recurrence was associated with significantly higher pre-CV CRP levels (odds ratio [OR] 1.84; 95% confidence interval [CI] 1.14 to 2.98; p = 0.013) even after adjusting for age (OR 2.22; 95% CI 1.25 to 3.93; p = 0.006), for gender (OR 1.89; 95% CI 1.16 to 3.09; p = 0.011), or duration of arrhythmia (OR 1.86; 95% CI 1.13 to 3.07; p = 0.015). On multivariate analysis, CRP was the only independent predictor of arrhythmia recurrence (OR 2.19; 95% CI 1.05 to 4.55; p = 0.036).
CONCLUSIONS: Our data suggest that high levels of CRP are associated with an increased risk of recurrence of AF within one month. These data support the hypothesis that anti-inflammatory interventions may help in maintenance of normal sinus rhythm after CV. These data also may have implications for the identification of patients who are most likely to experience substantial benefit from CV therapy for AF.
|
Abbreviations and Acronyms
| | AF = atrial fibrillation | | BB = beta blockers | | CCB = calcium channel blockers | | CI = confidence interval | | CRP = C-reactive protein | | CV = cardioversion | | OR = odds ratio |
|
This article has been cited by other articles:

|
 |

|
 |
 
J. Sanchez-Quinones, F. Marin, V. Roldan, and G.Y.H. Lip
The impact of statin use on atrial fibrillation
QJM,
November 1, 2008;
101(11):
845 - 861.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Dorian and B. N. Singh
Upstream therapies to prevent atrial fibrillation
Eur. Heart J. Suppl.,
September 1, 2008;
10(suppl_H):
H11 - H31.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Hogh, J. Joensen, J. S. Lindholt, M. R. Jacobsen, and L. Ostergaard
C-Reactive Protein Predicts Future Arterial and Cardiovascular Events in Patients With Symptomatic Peripheral Arterial Disease
Vascular and Endovascular Surgery,
August 1, 2008;
42(4):
341 - 347.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
E M Kallergis, E G Manios, E M Kanoupakis, H E Mavrakis, S G Kolyvaki, G M Lyrarakis, G I Chlouverakis, and P E Vardas
The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation
Heart,
February 1, 2008;
94(2):
200 - 204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Casaclang-Verzosa, B. J. Gersh, and T. S.M. Tsang
Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation.
J. Am. Coll. Cardiol.,
January 1, 2008;
51(1):
1 - 11.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Liu, G. Li, L. Li, and P. Korantzopoulos
Association Between C-Reactive Protein and Recurrence of Atrial Fibrillation After Successful Electrical Cardioversion: A Meta-Analysis
J. Am. Coll. Cardiol.,
April 17, 2007;
49(15):
1642 - 1648.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Ahlsson, L. Bodin, O. H. Lundblad, and A. G. Englund
Postoperative Atrial Fibrillation is Not Correlated to C-Reactive Protein
Ann. Thorac. Surg.,
April 1, 2007;
83(4):
1332 - 1337.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Klein, S. E. Jasper, W. E. Katz, J. F. Malouf, L. A. Pape, M. F. Stoddard, C. Apperson-Hansen, E. A. Lieber, and The ACUTE II Steering and Publications Committee F
The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: Assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study
Eur. Heart J.,
December 1, 2006;
27(23):
2858 - 2865.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, D. Sahn, and S. Tsimikas
Highlights of the Year in JACC 2005
J. Am. Coll. Cardiol.,
January 3, 2006;
47(1):
184 - 202.
[Full Text]
[PDF]
|
 |
|
|